NCT04987970View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 12, 2021

Primary Completion Date

November 11, 2021

Study Completion Date

November 27, 2021

Conditions
Hypertension and Dyslipidemia
Interventions
DRUG

CKD-386(2)

QD, PO

DRUG

D013, D326, D337

QD, PO

Trial Locations (1)

Unknown

H plus Yangji hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY